Related Experiment Video
Updated: Jul 5, 2025

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
Published on: July 24, 2013
Under-utilization of statins among people with HIV who were aged 40 years or older
Pei-Ying Wu1, Hsin-Yun Sun2, Yu-Shan Huang2
1Center of Infection Control, National Taiwan University Hospital, Taipei, Taiwan.
Insights
Many people living with HIV have a high risk of atherosclerotic cardiovascular disease (ASCVD). While many qualified for statin therapy, a significant number did not receive prescriptions, indicating a gap in preventative care.
Area of Science:
- Cardiology
- Infectious Diseases
- Public Health
Background:
- HIV infection is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD).
- Effective management of ASCVD risk factors is crucial for improving long-term outcomes in people with HIV.
- Current guidelines recommend statin therapy for individuals with elevated ASCVD risk.
Purpose of the Study:
- To assess the 10-year atherosclerotic cardiovascular disease (ASCVD) risk in a cohort of HIV-positive individuals.
- To determine the proportion of participants eligible for statin therapy based on established risk criteria.
- To evaluate the rate of statin prescription among eligible HIV-positive individuals.
Main Methods:
- Prospective cohort study involving 1629 HIV-positive participants from June 2022 to April 2023.
- Calculation of 10-year ASCVD risk using a validated risk assessment tool.
- Analysis of statin eligibility criteria and prescription patterns.
Main Results:
- The majority of participants (59.9%) had a low 10-year ASCVD risk (<5%).
- A significant proportion (27.0%) met the criteria for statin therapy (≥7.5% risk).
- Among those eligible for statins, only 38.8% were prescribed the therapy, highlighting a treatment gap.
Conclusions:
- A notable percentage of HIV-positive individuals exhibit elevated ASCVD risk, warranting preventative interventions.
- There is a significant underprescription of statin therapy among eligible HIV-positive individuals.
- Addressing this gap in statin prescribing is essential for mitigating cardiovascular risk in this population.
Abstract:
From June 2022 to April 2023, 1629 HIV-positive participants were assessed for the risk of atherosclerotic cardiovascular disease (ASCVD). The 10-year ASCVD risk of <5 %, 5 % to <7.5 %, ≥7.5 % to <20 % and ≥20 % were 59.9 %, 14.4 %, 20.7 % and 5.0 %, respectively; 440 (27.0 %) participants met the criteria for statin therapy, but only 171 (38.8 %) were prescribed statins.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Retrovirus Life Cycles
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Sexually Transmitted Infections
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Cholesterol: Significance and Regulation
Considering cholesterol and...

